Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 26;389(17):1626-1628.
doi: 10.1056/NEJMc2310347.

Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection

Oscar Bladh  1 , Nina Greilert-Norin  1 , Sebastian Havervall  1 , Ulrika Marking  1 , Katherina Aguilera  1 , Jessica J Alm  1 , Kim Blom  2 , Mikael Åberg  3 , Jonas Klingström  4 , Charlotte Thålin  5
Affiliations

Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection

Oscar Bladh et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Antibody Responses before and after Infection with the BA.2.86 Subvariant.
Panel A shows wild-type spike IgG levels in serum samples (solid lines) and wild-type spike IgA levels in nasal samples (dashed lines) in the index case, who contracted the BA.2.86 subvariant of SARS-CoV-2 (green), as compared with samples obtained from the COMMUNITY cohort of 2149 Swedish health care workers (gray). All samples were measured with the use of commercial electrochemiluminescence panels; antibody levels are reported in arbitrary units (AU) per milliliter. Antibody levels for the cohort are represented as geometric means with geometric standard deviations. Also shown are the results in the index case for serum wild-type nucleocapsid IgG levels (Panel B) and the BA.5 and wild-type spike serum IgG and nasal IgA levels (Panel C) before and after BA.2.86 infection. Since 6 months had passed between the collection of the samples in February and the diagnosis of BA.2.86 infection in August in the index case, there may have been a decrease in the antibody levels before the increase that was measured in September, so the boost after infection may have been underestimated. In Panels A and C, nasal spike IgA levels have been normalized to nasal total IgA levels.
See this image and copyright information in PMC

References

    1. Rasmussen M, Møller FT, Gunalan V, et al. First cases of SARS-CoV-2 BA.2.86 in Denmark, 2023. Euro Surveill 2023;28:2300460-2300460. - PMC - PubMed
    1. Scarpa F, Ciccozzi M. On the SARS-CoV-2 BA.2.86 lineage: a mutation point of view. J Med Virol 2023;95(9):e29079-e29079. - PubMed
    1. Marking U, Havervall S, Norin NG, et al. Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers. Nat Commun 2023;14:1577-1577. - PMC - PubMed
    1. Havervall S, Marking U, Svensson J, et al. Anti-spike mucosal IgA protection against SARS-CoV-2 omicron infection. N Engl J Med 2022;387:1333-1336. - PMC - PubMed
    1. Bladh O, Marking U, Havervall S, et al. Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose. Lancet Microbe 2023;4(7):e488-e488. - PMC - PubMed

Supplementary concepts